Drug evaluation: ProCord - a potential cell-based therapy for spinal cord injury

IDrugs. 2006 May;9(5):354-60.

Abstract

Proneuron Biotechnologies Inc is developing ProCord, an activated macrophage cell therapy, for the potential treatment of neurological conditions. In September 2004, ProCord was granted Orphan Drug status by the US Food and Drug Administration for the treatment of acute spinal cord injury.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell- and Tissue-Based Therapy*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Immunologic Factors / chemical synthesis
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use*
  • Neuroprotective Agents / chemical synthesis
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Quantitative Structure-Activity Relationship
  • Spinal Cord Injuries / therapy*

Substances

  • Immunologic Factors
  • Neuroprotective Agents